martes, 27 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 23, 2026

Ocham's Razor Capital Limited Announces Reverse Takeover Transaction With Pelican Canada Inc. and Brokered Financing

View original at finance.yahoo.com
Ocham's Razor Capital Limited Announces Reverse Takeover Transaction With Pelican Canada Inc. and Brokered Financing NOT FOR DISTRIBUTION TO U.S…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pelican operates in over 55 countries

    80% confidence
  • The resulting issuer will change its business to the current business of Pelican

    80% confidence
  • Pelican has over 25 years of experience in AI-driven payment processing and financial crime compliance

    80% confidence
  • Pelican has processed more than one billion transactions across various payment types and global banking standards

    80% confidence
  • The closing date of the offering is expected to occur on or about March 5, 2026

    80% confidence
  • Common shares of the Resulting Issuer issued to former holders of Subscription Receipts are anticipated to be free-trading, subject to applicable securities laws

    80% confidence
  • The net proceeds of the Offering will be used for working capital and general corporate purposes

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,994
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,994 hechos verificados con la fuente5,500 documentos fuente archivados
Consulta estos datos → isubstrate.com